The Asembia Specialty Pharmacy Summit (AXS25) once again proved why it’s considered a cornerstone event in the pharmaceutical and healthcare industry. Bringing together leaders and innovators from across the specialty pharmacy landscape, the conference offered valuable insights into the evolving dynamics of drug pricing, market access, and the specialty pipeline. Several members of the VS Health Group (VSHG) team were in attendance, and here are a few key takeaways from this year’s summit.
A Front-Row Seat to the Specialty Pipeline
One of the most highly anticipated sessions each year is the Specialty Pharmacy Pipeline presentation. This year, Brad McElya of Walgreens took the stage, stepping into big shoes left by Ray Tancredi — and he delivered. Brad’s comprehensive overview of assets in Specialty, Rare and Orphan, Oncology, and Gene and Cell therapy reinforced just how dynamic the space has become.
At VSHG, we were proud to see many of the therapies featured in Brad’s session align with our current work. We’re actively supporting market access efforts for two of the highlighted pipeline assets, demonstrating not only our deep expertise in the specialty space but also our readiness to help clients navigate its complexity.
Policy in Flux: What Pharma Needs to Know
Another standout session, “Beyond the Headlines: What Pharma Leaders Must Know About Tariffs, Supply Chains, and Policy Changes,” brought together a powerhouse panel including former Secretary of Veterans Affairs Dr. David Shulkin and two retired generals. Their discussion highlighted the volatility of the current policy landscape—tariffs, drug pricing reforms, and shifting supply chain priorities.
In just a few short weeks since Asembia, focus has shifted from tariffs to the implications of a new executive order on drug pricing. These rapid changes underscore a key message from the panel: adaptability is essential. For over 25 years, VSHG has supported pharma and biotech clients through pivotal moments of policy change—from MMA 2003 to the ACA to the Inflation Reduction Act (IRA). Our seasoned Account Directors continue to provide expert navigation through healthcare’s most complex regulatory waters.
Disruption on the Horizon: What PBMs and Payers Want Next
A recurring theme throughout the summit was disruption, specifically in how Pharmacy Benefit Managers (PBMs) and payers are evaluating new service models. With approximately one-fourth of PBM clients actively seeking alternative or disruptive solutions, the industry is clearly in a state of transition.
This message resonates with the mission of VSHG. Our team, composed of former executive-level payer and pharma decision-makers, is already helping clients anticipate and act on these shifts. From payer engagement strategies to developing forward-thinking market access plans, we’re helping organizations stay ahead of the curve.
Looking Ahead
Asembia AXS25 reaffirmed what we already know: the specialty pharmacy landscape is evolving faster than ever, and those who succeed will be the ones who adapt, anticipate, and act. At VSHG, we’re proud to partner with organizations that are ready to lead the change.
Do you have questions or would you like to learn how VSHG can support your market access strategies? Reach out to us here.